Charles Steenbergen Jr., M.D., Ph.D.

Headshot of Charles Steenbergen Jr.
  • Professor of Pathology
Male

Expertise

Cardiovascular Pathology, Pathology, Transplant Pathology ...read more

Research Interests

Cardiovascular Diseases, particularly Ischemia-Reperfusion Injury ...read more

Locations

The Johns Hopkins Hospital (Main Entrance)

1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-955-9790
The Johns Hopkins Hospital (Main Entrance) - Google Maps

Johns Hopkins Outpatient Center (now called Levi Watkins, Jr., M.D., Outpatient Center)

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue
Baltimore, MD 21224
Phone: 410-955-9790
Johns Hopkins Bayview Medical Center - Google Maps

Background

Dr. Charles Steenbergen is a professor of pathology at the Johns Hopkins University School of Medicine. He specializes in cardiovascular and transplant pathology, with particular focus on the mechanisms of ischemic heart disease.

Dr. Steenbergen received an M.D. and a Ph.D. from the University of Pennsylvania. He completed a residency in anatomic pathology and a fellowship in pathology at Duke University.

...read more

Titles

  • Professor of Pathology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; University of Pennsylvania School of Medicine (1978)

Residencies

  • Anatomic Pathology; Duke University Hospital (1984)

Board Certifications

  • American Board of Pathology (Anatomic Pathology) (1985)

Research & Publications

Research Summary

Dr. Steenbergen’s research focuses on mechanisms of ischemic heart disease, and in particular, endogenous mechanisms that can be activated to protect the heart during a subsequent episode of ischemia and reperfusion.

He is interested in identifying signal transduction pathways that are involved in cardioprotection, and understanding how these signaling pathways confer their protective effect.

His lab studies the mechanisms of injury involving ionic dysequilibrium, and has used magnetic resonance spectroscopic techniques to monitor ion concentrations in intact hearts during ischemia and reperfusion. Since infarct size is a major determinant of clinical outcome in patients with ischemic heart disease, the lab hopes that better understanding of these protective mechanisms will lead to the development of better therapies for patients with coronary artery disease and patients undergoing heart surgery.

Selected Publications

Murphy, E. and Steenbergen, C.: Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 2008; 88: 581-609.

Das, S., Ferlito, M., Kent, O.A., Fox-Talbot, K., Wang, R., Liu, D., Raghavachari, N., Yang, Y., Wheelan, S.J., Murphy, E., Steenbergen, C. Nuclear miRNA regulates the mitochondrial genome in the heart. Circ. Res. 2012; 110: 1596-1603.

Yano, T., Ferlito, M., Aponte, A., Kuno, A., Miura, T., Murphy, E., Steenbergen, C. Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling. Circ. Res. 2014; 114: 1268-1280.

Kohr, M.J., Murphy, E., Steenbergen, C. Glyceraldehyde-3-phosphate dehydrogenase acts as a mitochondrial trans-S-nitrosylase in the heart. PLoS One. 2014; 9: e111448.

Sun, J., Nguyen, T., Aponte, A.M., Menazza, S., Kohr, M.J., Roth, D. M. Patel, H.H., Murphy, E., Steenbergen, C. Ischemic preconditioning preferentially increases protein S-nitrosylation in subsarcolemmal mitochondria. Cardiovasc. Res. 2015; 106: 227-236.

Is this you? Edit Profile
back to top button